The National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health has awarded $7.8 million over the next five years to the Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) to support inventors across the country in developing, translating and testing microsystems-based point-of-care technologies to help improve patient care.

Point-of-care technologies are medical diagnostic tests performed outside the laboratory in close proximity to where a patient is receiving care. This allows health care providers to make clinical decisions more rapidly, conveniently and efficiently.

AMCE POCT , which is one of six sites in the U.S. selected by NIH as part of the NIH Point-of-Care Technologies Research Network, was originally established in 2018 to foster the development and commercialization of microsystems (microchip-enabled, biosensor-based, microfluidic) diagnostic tests that can be used in places such as the home, community or doctor’s office. The center played a pivotal role during the onset of the COVID-19 pandemic as the national test verification center to rapidly evaluate COVID-19 tests and help make them widely available.

“Our center was just getting its footing established when the pandemic began, and our unique combination of technical, laboratory and clinical expertise allowed us to rapidly pivot our focus and capabilities to address critical needs during the COVID-19 pandemic,” says Greg Martin, MD, one of the three principal investigators and a professor in the School of Medicine’s Division of Pulmonary, Allergy, Critical Care and Sleep Medicine.

Having facilitated the transformation in at-home and point-of-care diagnostics for COVID-19, ACME POCT will apply this experience and expertise to a broad range of health care needs.

“The pandemic has taught us – physicians, scientists, the public, and society as a whole – the importance of point-of-care technologies in rapid disease diagnosis and public health,” says Wilbur Lam, MD, PhD, pediatric hematologist and oncologist at  Children’s Healthcare of Atlanta,   professor of pediatrics and biomedical engineering at Emory University and Georgia Institute of Technology. “Our center is honored to continue its role as the technology-focused center within the NIH’s POCTRN and we’re excited to apply the lessons we’ve learned to foster POC technologies beyond COVID-19 to ultimately improve patient care and public health on multiple fronts.” 

The ACME POCT uniquely leverages Atlanta’s nationally top-ranked clinical programs at Emory Healthcare and Children’s Healthcare of Atlanta, one of the nation’s largest pediatric hospital systems, as well the internationally acclaimed microsystems expertise at the Georgia Institute of Technology.

Microsystems technologies have been employed to develop microfluidic technologies that enable the collection of microliter samples of fluid, such as blood, for downstream analysis. They have also proven useful in smartphones as sensors for medical applications and in wearable electronics, which enable “on patient” sensing of physiologic and biomedical signals.

Eric Vogel, PhD, principal investigator and Hightower Professor of Materials Science and Engineering at Georgia Tech, adds, “because of their small size(<1mm), low power requirements and advanced engineered materials, microsystems diagnostics provide portability that is vital for point-of-care testing. The NIH funding for ACME POCT enables microsystems-based POC inventors from across the country to refine their technology with the objective of accelerating the path to translation and clinical adoption.”

Since its founding in 2018, ACME POCT has funded 22 projects from 17 different institutions or companies. As Atlanta biomedical innovation has flourished in the last 4 years with the launch of the Emory/GT/Children’s  ADJUST Center  and the  AppHatchery clinical smartphone app  development program, ACME POCT aims to capitalize on this growing innovation ecosystem and use a “disease inclusive” approach to move the field of microsystems-based technologies forward in Atlanta and beyond.  

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: